Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2

Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2

Non-small cell lung cancer (NSCLC) caused more deaths in 2017 than breast cancer, prostate, and brain cancers combined. This is primarily due to their aggressive metastatic nature, leading to more fatal rates of cancer patients. Despite this condition, there are no clinically approved drugs that can...

Full description

Bibliographic Details
Main Authors: Chidiebere U. Awah, Joo Sun Mun, Aloka Paragodaarachchi, Baris Boylu, Martin Nzegwu, Hiroshi Matsui, Olorunseun Ogunwobi
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Oncology
Subjects:
NSCLC EGFRT790M
ERBB2/HER2
osimertinib and trastuzumab resistance
engineered mRNA destabilization
mRNA overwriting
iron oxide nanocages (IO)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1344852/full

Similar Items

Similar Items